Sentence: Sixty-two analyzable patients with predominantly intermediate-grade non-Hodgkin lymphoma received cyclophosphamide ( 200 mg/m(2 ) per day ) , doxorubicin ( 12.5 mg/m(2 ) per day ) , and etoposide ( 60 mg/m(2 ) per day ) ( CDE ) by continuous intravenous infusion for 4 days ( 96 hours ) every 3 weeks for a maximum of 8 cycles .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['cyclophosphamide', 'doxorubicin', 'etoposide'], 'is_context_needed': True}]